Till Erdmann

Founder & Managing Director, iDrug GmbH

Serial Founder, Angel Investor, IDrug Managing Director

Over 20 years life science experience in biopharma, diagnostics, digital health, and med-tech. Founder of Myelo Therapeutics, Treamid Therapeutics, and IDrug. Advises and invests in early-stage life sciences ventures. Hands-on experience in strategy development, general management and troubleshooting, fundraising, business development, and partnering. Over €40 Mio. venture capital and non-dilutive funding raised.

Prior to becoming a founder, Till worked in management consulting and subsequently in various strategy, marketing, and commercial roles at Bayer Pharma and Thermo Fisher Scientific. He is an engineer and MBA by training.